Aura Biosciences, Inc. (NASDAQ:AURA) Short Interest Update

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 1,280,000 shares, an increase of 20.8% from the December 15th total of 1,060,000 shares. Based on an average trading volume of 206,600 shares, the short-interest ratio is currently 6.2 days. Currently, 2.9% of the shares of the company are short sold.

Insiders Place Their Bets

In other news, insider Janet Jill Hopkins sold 11,822 shares of the stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $9.36, for a total value of $110,653.92. Following the completion of the transaction, the insider now directly owns 151,693 shares of the company's stock, valued at approximately $1,419,846.48. This represents a 7.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Los Pinos Elisabet De sold 9,200 shares of the company's stock in a transaction dated Tuesday, October 29th. The stock was sold at an average price of $10.74, for a total transaction of $98,808.00. Following the completion of the sale, the insider now directly owns 320,647 shares in the company, valued at approximately $3,443,748.78. The trade was a 2.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,575 shares of company stock valued at $215,401 in the last quarter. Insiders own 5.40% of the company's stock.

Institutional Investors Weigh In On Aura Biosciences

A number of hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. boosted its position in Aura Biosciences by 107.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company's stock worth $477,000 after buying an additional 27,718 shares during the period. Franklin Resources Inc. lifted its position in shares of Aura Biosciences by 14.8% in the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company's stock worth $15,571,000 after purchasing an additional 215,597 shares during the period. Barclays PLC boosted its stake in shares of Aura Biosciences by 256.5% in the 3rd quarter. Barclays PLC now owns 61,010 shares of the company's stock valued at $544,000 after purchasing an additional 43,897 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Aura Biosciences by 4.1% during the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company's stock worth $8,990,000 after buying an additional 39,379 shares during the period. Finally, Wellington Management Group LLP bought a new position in Aura Biosciences during the third quarter worth $1,037,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Stock Up 1.3 %

Shares of AURA traded up $0.10 during trading hours on Friday, hitting $7.77. The company had a trading volume of 112,088 shares, compared to its average volume of 132,090. The firm has a market cap of $388.11 million, a price-to-earnings ratio of -4.49 and a beta of 0.30. The business has a fifty day moving average of $8.68 and a 200-day moving average of $8.88. Aura Biosciences has a 12 month low of $6.63 and a 12 month high of $12.38.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, topping analysts' consensus estimates of ($0.44) by $0.02. On average, equities analysts expect that Aura Biosciences will post -1.66 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of Aura Biosciences in a research report on Thursday, November 14th. Cowen reiterated a "buy" rating on shares of Aura Biosciences in a research report on Friday, October 18th. BTIG Research boosted their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a "buy" rating in a research note on Friday, October 18th. Finally, Scotiabank raised their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a "sector outperform" rating in a research note on Friday, October 18th. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $23.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.